Treats symptoms of seasonal allergic rhinitis. ANDA 90423, held by Sun Pharm. Azelastine Hydrochloride.
As of Nov 16, 2026, ANDA 90423 (Azelastine Hydrochloride), held by Sun Pharm, was first approved by FDA on May 23, 2012, with 3 approved supplements and 0 published complete response letters.
Azelastine hydrochloride nasal solution (nasal spray), 0.1% (137 mcg per spray) is indicated for the treatment of the symptoms of seasonal allergic rhinitis in adults and pediatric patients 5 years and older, and for the treatment of the symptoms of vasomotor rhinitis in adults and adolescent patients 12 years and older.
| Date | Submission | Status | Documents |
|---|---|---|---|
| May 23, 2012 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Azelastine Hydrochloride0.137MG/SPRAY · spray, metered;nasal | Azelastine Hydrochloride | Discontinued |
| Apr 2, 2019 | Supplement 19Labeling · Standard review | Approved | None posted |
| Dec 22, 2016 | Supplement 14Manufacturing | Approved | None posted |
| Aug 22, 2016 | Supplement 9Labeling · Standard review | Approved | None posted |
| May 23, 2012 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters